Active Ingredient History
Romidepsin, sold under the brand name Istodax, is an anticancer agent used in cutaneous T-cell lymphoma (CTCL) and other peripheral T-cell lymphomas (PTCLs). Romidepsin is a natural product obtained from the bacterium Chromobacterium violaceum, and works by blocking enzymes known as histone deacetylases, thus inducing apoptosis. It is sometimes referred to as depsipeptide, after the class of molecules to which it belongs. Romidepsin is branded and owned by Gloucester Pharmaceuticals, a part of Celgene. Wikipedia
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Astrocytoma (Phase 1/Phase 2)
Brain Neoplasms (Phase 1/Phase 2)
Breast Neoplasms (Phase 2)
Breast Neoplasms, Male (Phase 2)
Burkitt Lymphoma (Phase 1/Phase 2)
Carcinoma, Islet Cell (Phase 2)
Carcinoma, Non-Small-Cell Lung (Phase 2)
Carcinoma, Renal Cell (Phase 2)
Carcinoma, Small Cell (Phase 1)
Carcinoma, Squamous Cell (Phase 2)
Chondrosarcoma (Phase 2)
Choroid Plexus Neoplasms (Phase 1)
Colorectal Neoplasms (Phase 2)
Craniopharyngioma (Phase 1)
Enteropathy-Associated T-Cell Lymphoma (Phase 1)
Ependymoma (Phase 1)
Esophageal Neoplasms (Phase 2)
Fibrosarcoma (Phase 2)
Gastrinoma (Phase 2)
Gastrointestinal Stromal Tumors (Phase 2)
Glioblastoma (Phase 1/Phase 2)
Glioma (Phase 1)
Gliosarcoma (Phase 1/Phase 2)
Glucagonoma (Phase 2)
Hamartoma (Phase 2)
Hematologic Neoplasms (Phase 1)
HIV (Phase 2)
HIV Infections (Phase 2)
Hodgkin Disease (Phase 1/Phase 2)
Inflammatory Breast Neoplasms (Phase 1/Phase 2)
Insulinoma (Phase 2)
Intestinal Neoplasms (Phase 2)
Intraocular Lymphoma (Phase 1/Phase 2)
Leiomyosarcoma (Phase 2)
Leukemia (Phase 2)
Leukemia, Hairy Cell (Phase 1/Phase 2)
Leukemia, Lymphocytic, Chronic, B-Cell (Phase 2)
Leukemia-Lymphoma, Adult T-Cell (Phase 2)
Leukemia, Myeloid, Acute (Phase 2)
Leukemia, Myeloid, Chronic-Phase (Phase 1)
Leukemia, Prolymphocytic, T-Cell (Phase 1/Phase 2)
Liposarcoma (Phase 2)
Lung Neoplasms (Phase 2)
Lymphoma (Phase 2)
Lymphoma, B-Cell (Phase 1)
Lymphoma, B-Cell, Marginal Zone (Phase 1/Phase 2)
Lymphoma, Extranodal NK-T-Cell (Phase 1)
Lymphoma, Follicular (Phase 2)
Lymphoma, Large B-Cell, Diffuse (Phase 1)
Lymphoma, Large-Cell, Anaplastic (Phase 2)
Lymphoma, Large-Cell, Immunoblastic (Phase 2)
Lymphoma, Mantle-Cell (Phase 2)
Lymphoma, Non-Hodgkin (Phase 2)
Lymphoma, T-Cell (Phase 3)
Lymphoma, T-Cell, Cutaneous (Phase 2)
Lymphomatoid Granulomatosis (Phase 1/Phase 2)
Medulloblastoma (Phase 1)
Melanoma (Phase 2)
Meningioma (Phase 1)
Mesothelioma (Phase 1)
Multiple Myeloma (Phase 2)
Mycosis Fungoides (Phase 1/Phase 2)
Myelodysplastic Syndromes (Phase 2)
Myeloproliferative Disorders (Phase 2)
Neoplasm Metastasis (Phase 2)
Neoplasms ()
Neoplasms, Germ Cell and Embryonal (Phase 1)
Neuroectodermal Tumors (Phase 1)
N-Myc Proto-Oncogene Protein (Phase 1)
Oligodendroglioma (Phase 1/Phase 2)
Osteosarcoma (Phase 2)
Ovarian Neoplasms (Phase 2)
Pancreatic Neoplasms (Phase 2)
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma (Phase 1/Phase 2)
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (Phase 1/Phase 2)
Prostatic Neoplasms (Phase 2)
Rhabdomyosarcoma (Phase 2)
Sarcoma (Phase 2)
Sarcoma, Ewing (Phase 2)
Sarcoma, Synovial (Phase 2)
Sezary Syndrome (Phase 2)
Small Cell Lung Carcinoma (Phase 2)
Somatostatinoma (Phase 2)
Spinal Cord Neoplasms (Phase 1)
Squamous Cell Carcinoma of Head and Neck (Phase 2)
Stomach Neoplasms (Phase 2)
Testicular Neoplasms (Phase 1/Phase 2)
Thyroid Neoplasms (Phase 2)
Triple Negative Breast Neoplasms (Phase 1/Phase 2)
Urethral Neoplasms (Phase 2)
Urinary Bladder Neoplasms (Phase 2)
Waldenstrom Macroglobulinemia (Phase 1/Phase 2)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
